Kolexia
Duruisseaux Michael Pneumologie
Duruisseaux Michael
Pneumologie
Hôpital Louis Pradel
Bron, France
539 Activités
562 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Adénocarcinome Carcinomes Adénocarcinome pulmonaire Métastase tumorale Adénocarcinome mucineux Carcinome épidermoïde

Collaborateurs

Voir plus
Cadranel Jacques
Cadranel Jacques
Hôpital Tenon, Paris, France
Moro-Sibilot Denis
Moro-Sibilot Denis
Hôpital Nord Grenoble, La Tronche, France
Wislez Marie
Wislez Marie
Hôpital Cochin, Paris, France
Girard Nicolas
Girard Nicolas
Clcc Institut Curie, Paris, France

Industries

Voir plus
AstraZeneca
29 collaboration(s)
Dernière en 2023
Amgen
17 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
13 collaboration(s)
Dernière en 2023
Janssen
12 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
ORAKLE: A Phase II Non-randomized, Single Group Assignment, Open-label, Multicenter Study of Efficacy and Safety of Lorlatinib Monotherapy After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   06 mars 2024
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK): A Phase II Randomized, Open-Labelled, Multicenter Study of Safety & Efficacy of Combination Brigatinib and Carboplatin-Pemetrexed Therapy or Brigatinib Monotherapy as First-Line Treatment in Advanced ALK-Positive Non-Small Cell Lung Cancer
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   06 mars 2024
SAVIMMUNE: A Phase II Single-arm Trial Evaluating Safety and Efficacy of Durvalumab in ECOG Performance Status 2-3, Treatment-naive, Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) and High PD-L1 Tumor Expression
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   06 mars 2024
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
Essai Clinique (Lilly)   27 février 2024
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Essai Clinique (Loxo Oncology, Inc.)   27 février 2024
ODYSSEE: Characterisation of TLR4+ Blood Cells in Patients With Solid Cancer
Essai Clinique (Hospices Civils de Lyon)   26 février 2024
SMALLHAN: Assessment of Tobacco Smoking and Alcohol Drinking and Treatment Outcomes Among Patients With Lung or Head and Neck Cancer
Essai Clinique (Hospices Civils de Lyon)   16 février 2024
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers.
NPJ precision oncology   16 février 2024
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring gene fusions.
Future oncology (London, England)   13 février 2024
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers: A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Malignant Tumors
Essai Clinique (BMS)   25 janvier 2024